A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)

About the trial

Sponsor

AbbVie

Tested

Adalimumab (drug), Upadacitinib (drug), Placebo to Upadacitinib (drug), Placebo to Adalimumab (drug)

Dates

Started 2017-04-27; completion 2024-09-09

Results posted

Yes

This study includes two periods. The main objective of Period 1 is to compare the efficacy of upadacitinib 15 mg once daily (QD) and 30 mg QD versus placebo and versus adalimumab (Humira®) in participants with moderately to severely active psoriatic arthritis (PsA) who have had an inadequate response to non-biologic DMARDs (DMARD-IR). Period 1 is also designed to compare the efficacy of upadacitinib 15 mg and 30 mg QD versus placebo for the prevention of structural progression. The objective of Period 2 is to evaluate the long-term safety, tolerability and efficacy of upadacitinib 15 mg and 30 mg QD in participants who have completed Period 1.

From ClinicalTrials.gov, last updated 2025-09-22. Full record, eligibility and contacts (opens in a new tab)

Industry funding

AbbVie Inc. reported $99,492 in research payments for this study in 2025 (15 payments).

Products named: Rinvoq

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.